There were no statistically significant differences in serum levels of IL-6 and IL-18 between the study groups (Table 3), which indicates that serum concentration of IL-6 and IL-18 are not good markers determining inflammation in patients with BPH + MetS. This evidence concerns the gene IL6 and benign prostatic hyperplasia.